在多巴胺对抗剂治疗过程中,叶椎间板裂变和阴囊病,用于治疗益生菌瘤
E A Giraldi1, A Saindane2, G Pradilla3
1Emory University School of Medicine, Dept. of Medicine, Division of Endocrinology, Metabolism and Lipids, Atlanta.
概括
多巴胺激动剂有效治疗乳腺瘤,但快速瘤缩很少会导致大脑. 密切监测和多学科决策对于在多巴胺激动剂治疗期间管理这种罕见并发症至关重要.
科学领域:
- 神经内分泌学神经内分泌学
- 神经外科 神经外科
- 眼科医生 眼科 眼科
背景情况:
- 多巴胺激动剂 (DA) 是对益生菌瘤的主要治疗方法.
- 虽然有效,但DA疗法很少会导致光学或脑,这是由于瘤体积的快速减少.
研究的目的:
- 为了强调多巴胺激动剂治疗前乳腺瘤期间脑的罕见并发症.
- 强调在这种情况下需要谨慎监测和多学科管理.
主要方法:
- 两名患有大型前性腺瘤的患者的病例报告,接受了多巴胺激动剂 (cabergoline) 治疗.
- 分析了详细的临床表现,生化和放射学发现,治疗调整和结果.
主要成果:
- 两位患者都经历了显著的瘤缩和甲蛋白水平降低与cabergoline.
- 一名患者出现了中间叶带和脑,需要手术.
- 第二名患者显示光学的低位移和绑定与视野缺陷,需要降低剂量.
结论:
- 大型前乳腺瘤中对多巴胺激动剂的快速瘤反应需要密切的临床和神经眼科监测.
- 建议在开始DA治疗3个月后重复MRI扫描,如果出现新的质量效应症状,则建议在3个月后或更早地重复MRI扫描.
- 关于降低DA剂量或治疗视力缺陷的外科手术的管理决策需要逐个,多学科的方法.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
290
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
290
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
319
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
319
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
743
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
743
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
642
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
642


